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Abstract 
It is well established that the circulation half-life of liposomes increases with increasing dose. This effect is commonly attributed to 
'saturation' of the fixed and free macrophages of the reticuloendothelial system resulting in reduced clearance rates. However, it is also 
known that the clearance rate of liposomes is dependent on the amount of associated blood protein, leading to the possibility that 
dose-dependent i creases in circulation lifetimes could be due to decreases in the amount of blood protein associated per liposome. In 
order to test this hypothesis, the protein binding and clearance properties of large unilamellar liposomes composed of distearoylphos- 
phatidylcholine/cholesterol and egg phosphatidylcholine/dioleoylphosphatidic cid/cholesterol were examined in mice. Liposomes 
were injected over a dose range of 10 to 1000 mg lipid/kg body weight, and the circulation lifetime and liver and spleen accumulation 
monitored. As expected, longer circulation half-lives were observed at higher doses for both liposome compositions. However, it was also 
found that at higher liposome doses, significantly less protein was bound per liposome. The results indicate that there is a limited pool of 
blood proteins that is able to interact with liposomes of a given composition. At higher lipid doses these blood proteins are distributed 
over more liposomes resulting in lower protein binding values and longer circulation lifetimes. 
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I .  Introduction 
Liposomes are important vehicles for drug delivery, 
particularly for anticancer drugs [1], antifungal agents [2] 
and antibacterial drugs [3]. Liposomes also exhibit consid- 
erable potential as gene and oligonucleotide delivery sys- 
tems [4]. However, a basic understanding of mechanisms 
whereby liposomes are recognized and cleared from the 
circulation has not been achieved. It has been shown that 
liposome clearance rates are dependent on factors such as 
lipid composition, vesicle size, and lipid dose [5-7]. It is 
well known that increased doses of liposomes lead to 
longer circulation lifetimes [8-12]. This effect is generally 
believed to result from 'saturation' of the fixed and free 
macrophages of the reticuloendothelial system (RES), 
Abbreviations: RES, reticuloendothelial system; PC, egg phospha- 
tidylcholine; CHOL, cholesterol; DOPA, dioleoylphosphatidic acid; 
DSPC, distearylphosphatidylcholine; LUV, large unilamellar vesicle; 
CHE, cholesteryl hexadecyl ether; HBS, Hepes-buffered saline; Hepes, 
4-(2-hydroxyethyl)- 1 -piperazineethanesulfonic ac d. 
* Corresponding author. Fax: + 1 (604) 8224843. 
0005-2736/96//$15.00 © 1996 Elsevier Science B.V. All rights reserved 
PH S0005-2736(96)00003-X 
which play a dominant role in the clearance process, 
resulting in decreased clearance rates. 
It is also well established that liposomes exhibit strong 
interactions with blood proteins [13-16]. This includes 
opsonins such as IgG [17], complement component C3 
[13,15,18], and fibronectin [19]. Furthermore, liposomes 
have been shown to bind blood proteins in amounts in- 
versely related to liposome clearance rates [15,20], where 
liposomes with low levels of bound blood proteins exhibit 
extended circulation lifetimes• This relation indicates that 
liposomes coated with a large amount of total blood 
protein have a higher probability of being recognized and 
cleared by RES cells. This leads to the possibility that 
increased oses of liposomes result in a decrease in the 
binding of proteins critical to immune recognition, which 
leads to extended circulation lifetimes• 
In the present study we have investigated liposome 
blood-protein interactions over a range of doses for two 
liposome formulations. These are egg phosphatidyl- 
choline/cholesterol/dioleoylphosphatidic acid (PC/  
CHOL/DOPA) which binds high levels of blood proteins, 
and distearylphosphatidylcholine/cholesterol (DSPC/  
CHOL), which binds much lower blood protein levels. Our 
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results indicate that dose-dependent i creases in the circu- 
lation lifetimes of both liposome formulations were accom- 
panied by decreases in the amount of protein associated 
per vesicle, suggesting that reduced clearance rates at high 
doses are directly attributable todecreased levels of blood 
proteins associated with the individual iposomes. 
2. Materials and methods 
2.1. Preparation of liposomes 
Large unilamellar vesicles (LUVs) were prepared at 
various concentrations by extrusion of freeze-thawed 
multilamellar vesicles through two stacked 100 nm poly- 
carbonate filters (Nuclepore, Pleasanton, CA, USA) using 
an extrusion device (Lipex Biomembranes, Vancouver, 
BC, Canada) [21]. DSPC/CHOL (55:45, mol%) and 
PC/CHOL/DOPA (35:45:20, mol%) liposomes were pre- 
pared in Hepes-buffered saline solution (HBS; 20 mM 
Hepes, pH 7.4, 145 mM NaC1) at 2-200 mM total lipid 
concentrations. The average size of these liposomes was 
100 + 30 nm as determined by quasielastic light scattering 
analysis using a Nicomp Model 270 Submicron Particle 
Sizer (Nicomp Instruments, Santa Barbara, CA, USA). 
Liposomes were radiolabelled using a lipid marker, 
[3H]cholesteryl hexadecyl ether (CHE) (10 ~Ci/30/zmol 
of total lipid) (NEN Research Products, Mississauga, Ont, 
Canada). This label is non-exchangeable and non-metabo- 
lizable in mice due to low levels of cholesteryl ester 
transfer protein activity [22-24]. Specific activities of lipo- 
some preparations were determined by standard liquid 
scintillation counting methods using a Beckman LS 3801 
Liquid Scintillation System (Beckman Instruments, Fuller- 
ton, CA, USA), and a colorimetric phosphorous assay [25]. 
Lipids (DSPC, DOPA and PC) were purchased from Avanti 
Polar Lipids (Pelham, AL, USA). Cholesterol (CHOL) was 
purchased from Sigma, St. Louis, MO, USA. All lipids 
were used without further purification. 
2.2. In vivo mouse biodistribution studies 
Liposome preparations (200 /zl) were administered via 
the dorsal tail vein of female CD-1 mice (20-25 g, Charles 
River, St. Constant, Que, Canada). At appropriate time 
points, mice were killed by exposure to carbon dioxide. 
Blood was removed by cardiac puncture and collected in 
ice-cold 1.5 ml microcentrifuge tubes, immediately cooled 
to 0°C to prevent coagulation and centrifuged to separate 
plasma from blood cell components (12000 rpm, 2 min, 
4°C). Plasma liposome concentrations were determined 
from the specific activity of the injected liposomes, using 
standard liquid scintillation counting techniques. Plasma 
volume was assumed to be 5% of total body weight. The 
principle organs of the RES (liver and spleen) were indi- 
vidually collected, weighed, and homogenized (10% ho- 
mogenates in saline) for 2 min using a Polytron homoge- 
nizer (Brinkman Instruments, Rexdale, Ont, Canada). 
Aliquots of the tissue homogenates (400 ~1) were added to 
500/zl of Solvable (NEN Research Products, Mississauga, 
Ont, Canada) in 7 ml glass scintillation vials and digested 
for 3 h at 50°C. Samples were subsequently decolorized 
for 3 h at room temperature by the addition of 100 ~1 of 
30% hydrogen peroxide. Finally, 5 ml of Ultima Gold 
scintillation fluid (Packard Instrument, Meriden, CT, USA) 
was added to the vials and the levels of [3H]cholesteryl 
hexadecyl ether (CHE) in the digested tissue samples were 
determined by standard liquid scintillation analysis. All in 
vivo analyses used four mice per time point. 
2.3. Isolation of liposomes from blood components 
Liposomes were retrieved from mouse plasma using an 
established 'spin column' procedure, described in detail 
elsewhere [26]. Briefly, Bio-Gel A-15m, 200-400 mesh 
(Bio-Rad, Richmond, CA, USA) was equilibrated with 
HBS and packed in 1.0 ml Tuberculin syringes with glass 
wool plugs. Aliquots of plasma (50 /zl), isolated at 2 min 
post injection, were immediately applied to these columns. 
Column fractions were collected in glass 13 × 100 mm 
culture tubes by the repetitive addition of 50/zl of HBS to 
the spin columns followed by centrifugation (1000 rpm for 
1 min). The eluate from each centrifugation step was 
considered to be one fraction. Liposomes eluted in frac- 
tions 6 and 7, and were pooled for subsequent use in 
protein analysis. 
2.4. Quantification of the amount of total protein associ- 
ated with recovered liposomes 
Liposome-associated proteins were extracted and delipi- 
dated according to the procedure described by Wessel and 
Flugge [27]. Delipidation was required to prevent interfer- 
ence with protein assay results. Protein was quantified 
using the Micro BCA Protein Assay Reagent Kit (Pierce 
Chemical, Rockford, IL, USA) in 0.5% SDS in Milli-Q 
(0.22 /xm) filtered water. Briefly, 1.0 ml of protein assay 
working reagent was added to 1.0 ml 0.5% SDS protein 
solution, and following a 60 min incubation at 60°C, the 
sample absorbance at 562 nm was compared to a bovine 
serum albumin standard curve (0-16 /xg/ml). Protein 
binding values (PB; g protein/mol lipid) were calculated 
from the lipid concentrations of the recovered liposomes. 
A minimum of three PB determinations were made for 
each lipid composition and dose. 
2.5. SDS-polyacrylamide g l electrophoretic analysis of 
proteins associated with liposomes 
Protein analysis was facilitated by SDS-polyacrylamide 
gel electrophoresis u ing a Mini-PROTEAN II Dual Slab 
C.D. Oja et aL / Biochimica et Biophysica Acta 1281 (1996) 31-37 33 
lOO l A oo ~I -  
PC:CHOL:DOPA DSPC:CHOL B 
80 g0 
O 
60 60 I ; , .  • = ) 
,-] 
~ 40 40 
20 20 
1 2 3 4 0 10 20 30 40 50 
Time (Hours) Time (Hours) 
Fig. 1. Plasma clearance (%) of liposomes of varying dose. LUVs (100 nm) containing trace amounts of [3H]cholesteryl hexadecyl ether were administered 
intravenously into CD-1 mice. At various times, plasma levels of LUVs were measured by analyzing aliquots of plasma using standard scintillation 
counting methods. Panel A depicts PC/CHOL/DOPA (35:45:20, mol%): 100 mg/kg, ((3); 200 mg/kg, (n); 500 mg/kg, (zx); 1000 mg/kg, (x7). 
Panel B depicts DSPC/CHOL (55:45, mol%) liposomes of varying dose: 10 mg/kg, (+), 50 mg/kg, (O); 100 mg/kg, (• ) ;  500 mg/kg, (• ) ;  and 1000 
mg/kg, ( • ). Each data point represents he average plasma recovery and standard eviation from four mice. 
Gel electrophoretic apparatus (Bio-Rad, Richmond, CA, 
USA). Delipidated protein samples were solubilized in 
SDS-reducing buffer (0.0625 M Tris-HC1, 10% (v/v) 
glycerol, 2% (w/v) SDS, 5% (v/v) /3-mercaptoethanol, 
0.125% (w/v) Bromophenol b ue), heated at 95°C, cooled 
and centrifuged prior to application on the gel. Plasma 
proteins were separated using Bio-Rad Mini-PROTEAN II 
Ready Gels, 4-20% polyacrylamide gradient, 0.375 M 
Tris-HC1, pH 8.8 with a 4% stacking gel (75 × 75 × 1.0 
mm). The gels were run at 150 V for 60 min. Protein 
molecular weights were estimated by comparison to High 
and Low Range Silver Stain SDS-PAGE Standards (Bio- 
Rad). The proteins were detected using an optimized sil- 
ver-staining procedure [28]. All gel mixtures and buffer 
solutions were prepared in Milli-Q (0.22 /xm filtered) 
water and degassed. Gel and buffer reagents were pur- 
chased from Bio-Rad. 
3. Results 
3.1. Biodistribution of increasing doses of DSPC / CHOL 
and PC/CHOL/DOPA liposomes 
The first set of experiments was aimed at characterizing 
the circulation longevity and tissue distribution of 100 nm 
diameter LUVs composed of PC/CHOL/DOPA 
(35:45:20, mol%) and DSPC/CHOL (55:45, mol%). These 
two lipid compositions were selected because of their 
dramatically different circulation clearance characteristics 
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Fig. 2. RES uptake (%) of liposomes of varying dose. LUVs (100 nm) containing trace amounts of [3H]cholesteryl hexadecyl ether were administered 
intravenously into CD-1 mice. At various times, liposome recovery in the liver and spleen was measured by counting aliquots of 10% HBS organ 
homogenates solubolized using a Solvable digestion procedure, using standard scintillation counting methods. Panel A depicts PC/CHOL/DOPA 
(35:45:20, mol%) liposomes of varying dose: 100 mg/kg, (O); 200 mg/kg, ([]); 500 mg/kg, (zx); 1000 mg/kg, (v).  Panel B depicts DSPC/CHOL 
(55:45, mol%) liposomes of varying dose: 10 mg/kg, (+); 50 mg/kg, (0); 100 mg/kg, (•) ;  500 mg/kg, (• ) ;  and 1000 mg/kg, (•) .  Each data point 
represents he average combined organ and spleen recovery and standard eviation from four mice. 
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Fig. 3. Total lipid uptake by the RES varying liposome dose. LUVs (100 nm) containing trace amounts of [3H]cholesteryl hexadecyl ether were 
administered intravenously into CD-1 mice. At various times, liposome recovery in the liver and spleen was measured by counting aliquots of 10% HBS 
organ homogenates solubolized using a Solvable digestion procedure, using standard scintillation counting methods. Panel A depicts PC/CHOL/DOPA 
(35:45:20, mol%) liposomes of varying dose: 100 mg/kg, (C)); 200 mg/kg, (v) ;  500 mg/kg, ([]); 1000 mg/kg, (A). Panel B depicts DSPC/CHOL 
(55:45, mol%) liposomes of varying dose: 10 mg/kg, (+);  50 mg/kg, (• ) ;  100 mg/kg, (0) ;  500 mg/kg, (• ) ;  and 1000 mg/kg, (• ) .  Each data point 
represents he average combined organ and spleen recovery and standard eviation from four mice. 
and protein binding behavior. The effects of increasing 
lipid dose up to 1000 mg lipid/kg body weight on the 
clearance from the circulation and organ biodistribution of
the liposomes were examined. As shown in Fig. 1, the 
clearance of DSPC/CHOL and PC/CHOL/DOPA LUVs 
from the circulation of CD-1 mice is consistent with earlier 
findings [15], in that DSPC/CHOL liposomes experience 
relatively long circulation lifetimes (Fig. 1B), while vesi- 
cles containing DOPA are very rapidly cleared (Fig. 1A). 
In both cases longer circulation lifetimes are observed as 
the dose is increased. Circulation half-lives for the 1000 
mg/kg doses of DSPC/CHOL and PC/CHOL/DOPA 
LUVs were 1200 and 80 min, respectively, as compared to 
360 min and 4 min for the 100 mg/kg doses. 
LUVs which are rapidly cleared from the circulation are 
accumulated by the RES organs (liver and spleen), as 
illustrated in Fig. 2. The lower percentage of liposome 
uptake observed with high liposome doses suggests satura- 
tion of the RES uptake pathways (Fig. 2). However, Fig. 3 
shows that despite the decreasing percentage of total lipo- 
some uptake observed, the amount of liposomes taken up 
by the principal organs of the RES (liver and spleen) still 
increases at higher doses. This pattern is consistent for 
both short- and long-lived lipid compositions (Fig. 3A and 
Fig. 3B), and is inconsistent with RES saturation. Esti- 
mates of initial liposome uptake rates for the liver also 
reflect he unsaturated nature of the RES, as illustrated in 
Fig. 4, which shows that the rates of liver uptake increased 
with the injected lipid dose over the full dose range for 
both compositions studied. 
3.2. Effect of liposome dose on PB values 
As previously noted, an inverse relationship exists be- 
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Fig. 4. Initial rate of liver uptake of liposomes of varying dose. LUVs (100 nm) containing trace amounts of [3H]cholesteryl hexadecyl ether were 
administered intravenously into CD-1 mice. Liposome recovery in the liver was subsequently measured and plotted over time. Estimates of the initial rates 
of liposome uptake by the liver were determined based on initial slope determinations from the uptake curves. Error bars represent the approximate d gree 
of uncertainty associated with the slope determination. Panel A (O) depicts PC/CHOL/DOPA (35:45:20, mol%) liposomes of varying dose. Panel B (O) 
depicts DSPC/CHOL (55:45, mol%) liposomes of varying dose. 
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Fig. 5. Relation of liposome-associated protein and the injected lipid 
dose. Aliquots of recovered liposomes were delipidated, and the extracted 
proteins quantified using the micro BCA protein assay (see Section 2). 
The liposomes were composed of PC/CHOL/DOPA (35:45:20, mol%) 
(©) and DSPC/CHOL (55:45, mol%) (O). The data points represent the 
average and standard eviation obtained from three separate trials. 
clearance rates from the circulation [15]. It was therefore 
of interest o determine whether the more slowly cleared 
high dose liposomes bound less blood protein. Liposomes 
were recovered from the blood at 2 min post-injection, and 
were subsequently delipidated and analyzed for associated 
protein using a BCA protein assay. Fig. 5 shows the Pa 
values as a function of lipid dose, for both compositions 
studied. A significant decrease in protein binding values is 
immediately apparent as the dose of each composition 
increases. When the protein binding values are expressed 
as a function of the liposome circulation half-lives (Fig. 6), 
the results are consistent with earlier observations [15]. 
High liposome doses exhibit lower PB values and signifi- 
cantly increased circulation lifetimes. These results there- 
fore support an inverse relationship between circulation 
half-lives and the amount of liposome-bound protein even 
for the same liposomes administered atdifferent doses. 
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Fig. 6. Relation of protein bound to liposomes and the circulation 
half-lives. Aliquots of recovered liposomes were delipidated, and the 
extracted proteins quantitated using the micro BCA protein assay (see 
Section 2). The liposomes were composed of PC/CHOL/DOPA 
(35:45:20, mol%): 100 mg/kg, (©); 200 mg/kg, (D); 500 mg/kg, (A); 
1000 mg/kg, (v )  and DSPC/CHOL (55:45, mol%) liposomes: 50 
mg/kg, (O); 100 mg/kg, (11); 500 mg/kg, (A); and 1000 mg/kg, 
(v) .  The data points represent the average and standard eviation 
obtained from three separate trials. Half-lives were determined by analy- 
sis of the plasma clearance data of Fig. 1. 
Fig. 6 also displays a unique pattern of PB versus 
half-life for each liposome composition. Liposome prepa- 
rations with the same PB value do not necessarily experi- 
ence the same clearance kinetics. At a PB value of 12 
g/mol, DOPA-liposomes (1000 mg/kg) possessed a 75 
min half-life, while DSPC/CHOL (200 mg/kg) exhibits a 
half-life of 450 min. Clearly, liposome clearance is depen- 
dent on the type, as well as the quantity, of protein bound. 
An important corollary of the observation that the 
amount of protein bound per LUV decreases as the dose 
increases, is that the total amount of blood protein avail- 
able for binding is limited. The total blood protein (/zg 
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Fig. 7. Relation of total protein bound to circulating liposomes and the injected ose. Aliquots of recovered liposomes were delipidated, and the extracted 
proteins quantitated using the micro BCA protein assay (see Section 2). Based on the PB values obtained, the total protein bound to each of the injected 
lipid samples was determined and plotted versus the injected lipid dose. Panel A (©) depicts liposomes composed of PC/CHOL/DOPA (35:45:20, 
mol%). Panel B (Q) depicts liposomes composed of DSPC/CHOL (55:45, mol%). The data points represent the average and standard eviation obtained 
from three separate trials. 
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Fig. 8. Silver-stained reducing SDS-PAGE gels of proteins associated 
with liposomes recovered from the circulation of CD-1 mice after 2 min 
post-injection. The proteins associated with the liposomes were separated 
electrophoretically on 4-20% SDS-polyacrylamide g ls and visualized by 
silver stain. Each lane of Panel A consists of 2 /zg of total protein 
isolated from PC/CHOL/DOPA (35:45:20, mol%) liposomes injected at 
the following doses: 100 mg/kg (lane 1), 500 mg/kg (lane 2), and I000 
mg/kg (lane 3). Panel B consists of 2 /zg protein samples isolated from 
DSPC/CHOL (55:45, mol%) liposomes injected at the following doses: 
100 mg/kg (lane 1), 500 mg/kg (lane 2), and 1000 mg/kg (lane 3). 
Lane M contains silver-stained SDS-PAGE molecular weight standards 
from Bio-Rad (myosin, 200 000; /3-galactosidase, 116 250; phosphorylase 
b, 97400; serum albumin, 66200; ovalbumin, 45000; carbonic anhy- 
drase, 31000; trypsin inhibitor, 21500; and lysozyme, 14400). Lane S 
contains normal mouse serum. 
is illustrated in Fig. 7. It is apparent the maximum amount 
of blood protein bound to the PC/CHOL/DOPA vesicles 
is approx. 550 _+ 70 /xg (Fig. 7A), whereas DSPC/CHOL 
vesicles bind a total of 60 ___ 10 /xg (Fig. 7B). This indi- 
cates that a limited pool of blood proteins is available to 
bind to liposomes of a given lipid composition, regardless 
of dose. At higher doses, these proteins are redistributed 
over a greater number of liposomes, resulting in lower PB 
values and reduced RES uptake. 
3.3. Influence of bound protein composition on clearance 
Fig. 8 shows the silver stained SDS-PAGE profiles of 
in vivo protein samples obtained from liposomes com- 
posed of PC/CHOL/DOPA and DSPC/CHOL isolated 
at 2 min post-injection. Comparison of protein composition 
was simplified by examining equal protein quantities (2 
/~g total protein/lane). As may be observed, the liposome 
composition has a significant influence on the profile of 
liposome-associated blood proteins. It is interesting to note 
that different doses of the same lipid composition pro- 
duced relatively minor changes in the plasma protein 
profile. 
4. Discussion 
In agreement with earlier work [10-12], this study 
reports increases in the circulation half-lives of liposomes 
as the lipid dose is increased. However, it was widely 
believed that this dose effect is a result of RES saturation 
[10,29]. As clearly demonstrated in this work, increased 
lipid dose results in decreased protein binding. Previously, 
we have demonstrated that PB values are inversely corre- 
lated with circulation lifetimes [15]. Together this suggests 
that the prolonged circulation lifetimes observed with in- 
creasing liposome dose are the direct result of the de- 
creased protein binding. 
Comparisons between DSPC/CHOL and PC/  
CHOL/DOPA liposomes at equivalent doses make it quite 
evident hat both the total lipid accumulation and the rate 
of lipid uptake by the RES, are up to 10-times greater for 
the DOPA-containing systems (Figs. 3 and 4). If the 
mechanisms of clearance for the two different liposome 
compositions both rely on uptake by the free and fixed 
macrophages of the RES, then the DOPA systems reflect 
at most the minimum capacity of the RES to take up 
liposomes. This capacity is not reached by the 
DSPC/CHOL liposomes, suggesting that RES saturation 
cannot account for the increased lifetimes of higher doses 
of DSPC/CHOL liposomes. Consequently, either the 
DOPA-containing liposomes are removed from the circula- 
tion by a different mechanism or the quantity and type of 
blood protein that associates with each liposome is of 
critical importance in establishing RES phagocytic ability. 
A number of recent investigations have focused on the 
importance of blood protein-liposome interactions [15,30- 
32]. Blood opsonins have long been known to be involved 
in the phagocytosis of foreign particulate matter [8,33], and 
Chonn et al. [15] demonstrated an inverse relationship 
between the blood protein associated with liposomes and 
the circulation half-lives. When dose-dependent circulation 
half-lives are examined, the results presented here also 
reflect an inverse relationship with the protein bound. 
Analysis of plasma protein binding over a range of dose 
reveals 8-12-fold increased protein binding to low doses 
of liposomes compared to high doses, for both 
DSPC/CHOL and PC/CHOL/DOPA liposomes (Fig. 5). 
Just as low protein binding lipid compositions have previ- 
ously been associated with enhanced circulation half-lives 
[15], high lipid doses with low PB values experienced 
similar extended lifetimes. This is likely because low PB 
values decrease the probability that the liposomes can be 
recognized and ingested by the RES. The blood opsonins 
on liposomal membranes are 'diluted' over a much greater 
surface area at higher lipid doses, as represented by the 
reduced Pa values. 
An important result of this work is the apparent exis- 
tence of specific and finite pools of plasma proteins that 
are available for binding to liposomes with different lipid 
compositions. Previous work has clearly illustrated that 
lipid composition strongly influences protein binding, both 
in total amount of protein bound and in terms of protein 
profiles. By varying only liposome dose, the results pre- 
sented here show that the total quantity of liposome-bound 
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blood protein reaches a plateau at higher doses (Fig. 7). 
Furthermore, the protein composition of this liposome-as- 
sociated protein does not significantly vary with dose (Fig. 
8). This suggests that the blood protein pools are specific 
in quantity and identity for each lipid composition. The 
DOPA-containing liposomes interact strongly with blood 
proteins, and the associated protein composition has been 
shown to be enriched in known blood opsonins [15]. 
DSPC/CHOL liposomes are low protein binding systems, 
and do not bind known opsonins with the same affinity of 
the high protein binding systems [15]. It should be noted 
that the maximum amount of blood protein bound, at any 
liposome composition or dose, was 0.6 mg/ml plasma. 
This is approx. 1% of the total plasma protein, 60-80 
mg/ml, calculated based on a plasma protein concentra- 
tion of 6-8 g/dl  [34] and assuming a plasma volume of 
5% of body weight. Although this represents only 1% of 
total blood protein, LUVs interact with major (albumin) 
[13] and minor (/32-glycoprotein- 1, IgG, and C3) [35,13,15] 
protein components in the blood. Some of the minor 
components of the blood can be depleted at these levels of 
protein bound, increasing the possible in vivo significance 
of binding otherwise small amounts of total blood protein. 
In summary, the studies described here illustrate the 
importance of liposome-bound blood proteins in mediating 
liposome clearance from the blood circulation and the role 
of membrane lipid composition as a factor regulating 
blood protein interactions. Different doses of the same 
liposomes lead to different blood protein binding proper- 
ties, consistent with the hypothesis that the amount of 
bound protein dictates the liposome clearance properties. 
Low PB values associated with high doses of liposomes 
which exhibit extended circulation times, suggest that the 
'saturation' phenomena may in fact be a consequence of
the depletion of blood opsonins, and not a result of RES 
saturation. This is further substantiated by the existence of 
a limited pool of blood proteins that is available for 
binding to liposomes. 
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